Business
OncoQuest Announces Enrollment of First Patient in Phase 1/2 Clinical Study Using Combination of Oregovomab with Checkpoint Inhibitor Nivolumab in Recurrent Ovarian Cancer
OncoQuest Announces Enrollment of First Patient in Phase 1/2 Clinical Study Using Combinat...
About this update from Quest Pharmatech Inc.
[{"type":"text","content":"\n\n\n\nOncoQuest Announces Enrollment of First Patient in Phase 1/2 Clinical Study Using Combination of Oregovomab with Checkpoint Inhibitor Nivolumab in Recurrent Ovarian Cancer\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nEDMONTON, May 9, 2017\n\n\n\nTSX Venture: QPT\n\n\n\nEDMONTON, May 9, 2017 /CNW/ - Quest PharmaTech Inc.  (TSX-V:  QPT)  (\"Quest\" or the \"Company\"), today announces that its subsidiary, OncoQuest Inc. (\"OncoQuest\"), a biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of cancer, has completed the enrollment of the first patient in a Phase 1/2 clinical study to evaluate the use of oregovomab in combination with Nivolumab, an anti-PD1 human monoclonal antibody which works as a checkpoint inhibitor in ovarian cancer patients in the recurrent setting.  This clinical trial is being conducted at the National Cancer Centre in Singapore (\"NCCS\"), with Dr. Tira Tan as Principal Investigator, Adjunct Associate Professor John Chia from Oncocare Cancer Centre as the Study Chair, and Dr. Jack Chan as the co-chair.\n\n\"We are extremely excited about launching this study,\" noted Dr. John Chia. \"Ovarian cancer is a lethal disease, and this trial may offer new hope for our patients. Early clinical data suggests that oregovomab may improve the immune system's processing of cancer antigens, and enhance the immune ability to recognize these cancer targets. We believe that the combination of oregovomab and Nivolumab, which amplifies such immune activity, will have a synergistic effect to elicit a higher quality tumor immune response, and hence improve control of the cancer.\" This will be the first clinical trial testing the combination of oregovomab with a checkpoint inhibitor as potential treatment of ovarian cancer in the recurrent setting. \n\n\"We continue to explore the potential of oregovomab in various stages of the progression of ovarian cancer,\" said Dr. Madiyalakan, CEO of Quest and OncoQuest. In frontline ovarian cancer, OncoQuest has ...